SCHEMBL5367616

SCHEMBL5367616

NCCCCCCNC(=O)C(F)(F)F

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.79
KMT2A Q03164 1/20 0.79
ALDH1A1 P00352 2/20 0.75
SMN1; SMN2 Q16637 2/20 0.75
POLB P06746 1/20 0.75
EPHX1 P07099 1/20 0.66
CA3 P07451 2/20 0.64
CA5A P35218 2/20 0.64
CA5B Q9Y2D0 2/20 0.64
CA14 Q9ULX7 2/20 0.64
CA12 O43570 1/20 0.64
CA2 P00918 1/20 0.64
CA4 P22748 1/20 0.64
CA6 P23280 1/20 0.64
CA7 P43166 1/20 0.64
CA9 Q16790 1/20 0.64
PAOX Q6QHF9 2/20 0.55
HDAC6 Q9UBN7 1/20 0.50
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19781069 1.00 MEN1 (0.79) MEN1KMT2AALDH1A1SMN1; SMN2POLB
Hydrochloric Acid SCHEMBL28974271 0.98 MEN1 (0.76) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL6490885 0.98 ALDH1A1 (0.78) MEN1KMT2AALDH1A1SMN1; SMN2POLB
Hydrochloric Acid SCHEMBL29241679 0.96 SMN1; SMN2 (0.75) MEN1KMT2AALDH1A1SMN1; SMN2POLB
Trifluoroacetic Acid SCHEMBL30387588 0.94 MEN1 (0.70) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL3149189 0.91 ALDH1A1 (0.74) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL11981741 0.90 CA5A (0.81) MEN1KMT2AALDH1A1SMN1; SMN2POLB
Hydrochloric Acid SCHEMBL29241548 0.89 SMN1; SMN2 (0.71) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL29982917 0.89 MEN1 (1.00) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL27889238 0.87 ALDH1A1 (1.00) MEN1KMT2AALDH1A1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2914607-B1 PHOTOCLEAVABLE LINKER MOLECULES WITH DIARYLSULPHID BACKBONE FOR TRANSIENT BIOCONJUGATE SYNTHESIS VENTANA MED SYST INC (US) 2017-11-29 EP disclosed
US-9790243-B2 Photocleavable linker molecules with diarylsulphide backbone for transient bioconjugate synthesis VENTANA MEDICAL SYSTEMS, INC. (US) 2017-10-17 US disclosed
US-20150284415-A1 PHOTOCLEAVABLE LINKER MOLECULES WITH DIARYLSULPHID BACKBONE FOR TRANSIENT BIOCONJUGATE SYNTHESIS VENTANA MED SYST INC (US) 2015-10-08 US disclosed
EP-2914607-A1 PHOTOCLEAVABLE LINKER MOLECULES WITH DIARYLSULPHID BACKBONE FOR TRANSIENT BIOCONJUGATE SYNTHESIS Ventana Medical Systems, Inc. (US) 2015-09-09 EP disclosed
WO-2014053397-A1 PHOTOCLEAVABLE LINKER MOLECULES WITH DIARYLSULPHID BACKBONE FOR TRANSIENT BIOCONJUGATE SYNTHESIS ROCHE DIAGNOSTICS GMBH (DE) 2014-04-10 WO disclosed
US-8680062-B2 System for delivering therapeutic agents into living cells and cells nuclei Deliversir Ltd. (IL) 2014-03-25 US disclosed
US-8680062-B2 System for delivering therapeutic agents into living cells and cells nuclei Deliversir Ltd. (IL) 2014-03-25 US disclosed
US-20080004234-A1 System for delivering therapeutic agents into living cells and cells nuclei SEGEV LABORATORIES LIMITED (IL) 2008-01-03 US disclosed
US-20080004234-A1 System for delivering therapeutic agents into living cells and cells nuclei SEGEV LABORATORIES LIMITED (IL) 2008-01-03 US disclosed
US-7223833-B1 Peptide nucleic acid conjugates ISIS PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
WO-1996011205-A1 PEPTIDE NUCLEIC ACID CONJUGATES ISIS PHARMACEUTICALS, INC. (US) 1996-04-18 WO disclosed
US-5156840-A Covalently attached to an antibody CYTOGEN CORPORATION (US) 1992-10-20 US disclosed
EP-0088695-B1 ANTIBODY CONJUGATES CYTOGEN CORPORATION (US) 1992-06-03 EP disclosed
EP-0175617-B1 ANTIBODY-THERAPEUTIC AGENT CONJUGATES CYTOGEN CORPORATION (US) 1991-10-30 EP disclosed
US-4867973-A DRUG DELIVERY CYTOGEN CORPORATION (US) 1989-09-19 US disclosed
WO-1986001720-A1 ANTIBODY THERAPEUTIC AGENT CONJUGATES CYTOGEN CORPORATION (US) 1986-03-27 WO disclosed
EP-0175617-A2 Antibody-therapeutic agent conjugates CYTOGEN CORPORATION (US) 1986-03-26 EP disclosed
EP-0088695-A2 Antibody conjugates CYTOGEN CORPORATION (US) 1983-09-14 EP disclosed
US-4243605-A RADIOIMMUNOASSAY, LABELS UNION CARBIDE CORPORATION (US) 1981-01-06 US disclosed
US-4115539-A RADIOIMMUNOASSAY, REACTION PRODUCT WITH ISOCYANATES UNION CARBIDE CORPORATION (US) 1978-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284415-A1 PHOTOCLEAVABLE LINKER MOLECULES WITH DIARYLSULPHID BACKBONE FOR TRANSIENT BIOCONJUGATE SYNTHESIS DHFR, DTYMK, DNPEP MEN1 2927/4885KMT2A 1482/4885ALDH1A1 2382/4885
US-20080004234-A1 System for delivering therapeutic agents into living cells and cells nuclei RCC1, NUMA1, ACIN1 MEN1 1982/4885KMT2A 4420/4885ALDH1A1 3923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.